Research
Hormonal
GDF15, a member of the TGF-β superfamily, acts as a central regulator of appetite and a potential treatment for obesity by reducing food intake and stimulating lipolysis.
GDF15 is a hormone that reduces food intake and increases fat burning. Research suggests it could be a future treatment for obesity, offering a different mechanism from current drugs.
ModerateSupportsMEDIUM confidence
GDF15, a member of the TGF-β superfamily, has been identified as a central regulator of appetite and a potential target for the treatment of obesity.
Why this rating
Evidence is from mouse models and xenografts; clinical translation is still emerging.
Source
Signaling pathways in obesity: mechanisms and therapeutic interventions
Xue Wen et al. · Signal Transduction and Targeted Therapy · 2022
DOI 10.1038/s41392-022-01149-x
narrative_reviewCited 386×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- GLP-1 receptor agonists (e.g., Liraglutide) reduce appetite and improve glucose tolerance by stimulating anorexigenic POMC/CART neurons and suppressing orexigenic AgRP/NPY neurons via cAMP and GABA-dependent signaling pathways.Good
- The MAPK signaling pathway (specifically ERK, JNK, and p38) plays a complex, context-dependent role in obesity, regulating appetite, adipogenesis, and insulin resistance, with effects varying between in vitro and in vivo models.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →